Business
Redwood Scientific Technologies Inc. (RSCI.OTC.PK) Announces Successful S1 Registration Filing and Provides Updates on TBX FREE Clinical Trial Progress
Redwood Scientific Technologies Inc. (RSCI.OTC.PK) Announces Successful S1 Registration Filing and Provides Updates on TBX FREE Clinical Trial Progress.
About this update from Redwood Scientific Technologies, Inc.
[{"type":"text","content":"\n\n\n\nRedwood Scientific Technologies Inc. (RSCI.OTC.PK) Announces Successful S1 Registration Filing and Provides Updates on TBX FREE Clinical Trial Progress\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nRedwood Scientific Technologies Inc. (RSCI.OTC.PK) Announces Successful S1 Registration Filing and Provides Updates on TBX FREE Clinical Trial Progress\nPR Newswire\nNEW YORK, Sept. 18, 2023\n\n\n\nNEW YORK, Sept. 18, 2023 /PRNewswire/ -- Redwood Scientific Technologies is delighted to announce the successful filing of its S1 registration statement with the Securities and Exchange Commission (SEC). The company has received confirmation from the SEC, affirming the completion of this important milestone. Jason Cardiff, Company President, expressed his enthusiasm regarding the S1 Filing, stating, \"This marks a significant milestone in our journey and brings us one step closer to achieving our goals.\"\n\n \n \n \n \n \n \n\n \nRedwood Scientific Technologies files S1 and updates on Clinical Trial process.Mr. Cardiff further provided updates on the progress of the clinical trials process for TBX FREE and TBX VAPE FREE. He stated, \"In our unwavering commitment to advancing medical science and enhancing customer outcomes, we have made substantial strides in our clinical trials process. We have now finalized the Institutional Review Board (IRB) documents required for submission, in accordance with the guidelines of the Food and Drug Administration (FDA). We eagerly anticipate delivering comprehensive scientific data that will benefit customers and healthcare providers alike.\"\nFor further information, please contact:Email: [email protected]: 646-503-7884\n\n\n\n\n\n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/redwood-scientific-technologies-inc-rsciotcpk-announces-successful-s1-registration-filing-and-provides-updates-on-tbx-free-clinical-trial-progress-301930457.html\nSOURCE Redwood Scientific Technologies Inc.\n\n\n\n\n","length":4284,"tagName":"div"}]